All members of the Expert Panel complied with American Society of Clinical Oncology (ASCO) policy on conflicts of interest, which requires disclosure of any financial or other interest that might be construed as constituting an actual, potential, or apparent conflict. Members of the Expert Panel completed ASCO's disclosure form and were asked to reveal ties to companies developing products that might be affected by promulgation of the guidelines. Information was requested regarding employment, consultancies, stock ownership, honoraria, research funding, expert testimony, and membership on company advisory committees. The Panel made decisions on a case-by-case basis as to whether an individual's role should be limited as a result of a conflict. No limiting conflicts were identified.
Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors in the original journal of publication.
Employment or Leadership Position: None Consultant or Advisory Role: Ajay Kakkar, Sanofi-aventis (C), Pfizer (C), Eiasi Pharmaceuticals (C); Howard Liebman, laxoSmithKline (C), Pfizer (C), Bristol-Myers Squibb (C); Gary Raskob, Sanofi-aventis (C), Bayer (C), Bristol-Myers Squibb (C), Boehringer-Ingelheim (C), Darichi (C), Takeda (C); Charles W. Francis, Eisai Pharmaceuticals (C) Stock Ownership: None Honoraria: Alok A. Khorana, Sanofi-aventis, Eisai Pharmaceuticals; Ajay Kakkar, Sanofi-aventis, Pfizer, Eiasi Pharmaceuticals; Howard Liebman, GlaxoSmithKline, Pfizer, Pharmion; Gary Raskob, Sanofi-aventis, Bayer, Boehringer-Ingelheim; Charles W. Francis, Eisai Pharmaceuticals Research Funding: Ajay Kakkar, Sanofi-aventis; Mark N. Levine, Pfizer; Howard Liebman, Bristol-Myers Squibb, Pharmion, Pfizer Expert Testimony: Daniel Clarke-Pearson (C); Mark N. Levine (C); Gary Raskob (C) Other Remuneration: None